Berenberg Bank set a $96.00 price objective on Gilead Sciences, Inc. (NASDAQ:GILD) in a report released on Thursday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Gilead Sciences from a hold rating to a sell rating in a report on Wednesday, October 18th. Vetr raised shares of Gilead Sciences from a buy rating to a strong-buy rating and set a $91.98 price target on the stock in a report on Friday, October 13th. Barclays PLC reaffirmed an overweight rating and issued a $90.00 price target on shares of Gilead Sciences in a report on Wednesday, October 11th. Morgan Stanley reaffirmed an equal weight rating and issued a $83.00 price target (up from $77.00) on shares of Gilead Sciences in a report on Friday, October 6th. Finally, Leerink Swann lifted their price target on shares of Gilead Sciences from $87.00 to $89.00 and gave the stock a market perform rating in a report on Thursday, October 5th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $85.64.

Gilead Sciences (NASDAQ GILD) traded down 0.5574% during trading on Thursday, reaching $80.7573. The company had a trading volume of 2,151,532 shares. The stock has a market capitalization of $105.46 billion, a P/E ratio of 8.7713 and a beta of 1.14. The stock has a 50 day moving average of $82.63 and a 200-day moving average of $72.65. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. During the same period in the previous year, the company earned $3.08 earnings per share. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. On average, analysts forecast that Gilead Sciences will post $8.74 earnings per share for the current fiscal year.

WARNING: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/23/gilead-sciences-inc-gild-given-a-96-00-price-target-by-berenberg-bank-analysts.html.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Shareholders of record on Friday, September 15th were paid a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.56%. Gilead Sciences’s payout ratio is 22.58%.

In other news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.56, for a total transaction of $6,054,372.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the transaction, the executive vice president now owns 106,113 shares of the company’s stock, valued at approximately $8,051,854.44. The disclosure for this sale can be found here. Insiders have sold 446,819 shares of company stock valued at $36,338,919 in the last 90 days. Insiders own 1.30% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in GILD. Sanders Capital LLC bought a new position in shares of Gilead Sciences during the third quarter worth about $427,585,000. Parnassus Investments CA grew its position in shares of Gilead Sciences by 37.4% during the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after acquiring an additional 4,556,901 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Gilead Sciences by 9.8% during the first quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock worth $2,076,368,000 after acquiring an additional 2,727,063 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Gilead Sciences by 35.0% during the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after acquiring an additional 2,700,600 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after acquiring an additional 2,148,697 shares during the last quarter. Institutional investors and hedge funds own 73.97% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.